ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
- None.
- None.
The introduction of ReShape Lifesciences' Lap-Band® 2.0 FLEX represents a significant advancement in the field of bariatric surgery devices. The new feature, which acts as a relief valve to alleviate discomfort from swallowing large pieces of food, could potentially reduce the frequency of in-office band adjustments. This innovation is likely to enhance patient compliance and satisfaction, which are critical factors in the success of weight loss interventions. From a business perspective, the Lap-Band® 2.0 FLEX could drive increased demand for Lap-Band® surgeries, as suggested by the initial surgeon feedback. This, in turn, could lead to revenue growth for ReShape Lifesciences.
Considering the obesity epidemic and the growing market for weight loss solutions, the Lap-Band® 2.0 FLEX could capture a significant market share if it demonstrates improved patient outcomes compared to existing alternatives. However, the long-term success of this product will depend on clinical data supporting its safety and efficacy, as well as the company's ability to navigate the regulatory landscape and secure insurance coverage for patients.
The launch of the Lap-Band® 2.0 FLEX by ReShape Lifesciences is a strategic move that could position the company as a leader in the metabolic health solutions space. The emphasis on patient experience and the reduction of post-operative adjustments addresses two major concerns in bariatric surgery: patient comfort and long-term maintenance. If the Lap-Band® 2.0 FLEX delivers on its promises, it could set a new standard in the industry, prompting competitors to innovate further.
From an investment standpoint, ReShape Lifesciences' stock (Nasdaq: RSLS) may see increased investor interest as the product gains traction in the market. The success of the initial surgeries and the positive surgeon testimonials provide a compelling narrative for potential growth. Nevertheless, investors should monitor the adoption rate of the Lap-Band® 2.0 FLEX and the company's sales performance in subsequent quarters to gauge the actual impact on the company's financial health.
The introduction of the FLEX technology in the Lap-Band® 2.0 is a noteworthy development in bariatric surgery, a field where incremental improvements can have significant implications for patient outcomes. The ability of the band to momentarily relax and allow the passage of larger food pieces could lead to a reduction in the common complications associated with gastric banding, such as esophageal dilation or band slippage. This self-correcting feature might also decrease the incidence of emergency interventions for food obstructions, which are not only distressing for patients but also costly for healthcare systems.
As a bariatric surgery specialist, the potential impact of the Lap-Band® 2.0 FLEX on patient adherence and long-term weight management is promising. However, rigorous clinical trials and long-term follow-up studies will be essential to validate these preliminary findings and to ensure that the new design does not introduce unforeseen complications. The medical community will be closely watching for peer-reviewed data on the safety and effectiveness of this new device.
FLEX Technology Designed to Enhance the Patient Experience
Surgeon Training Underway for the Initial Launch of the Lap-Band® 2.0 FLEX
IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas, Fort Worth, TX, and Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of NYU Langone Health’s Weight Management Program and Chief of the Division of Bariatric Surgery, have successfully performed the first surgeries utilizing the company’s next generation, enhanced Lap-Band® 2.0 FLEX.
“The first surgeries utilizing the Lap-Band® 2.0 FLEX mark, not only a seminal moment in the company’s launch of this enhanced product, but also a leap forward in improving the Lap-Band® patient experience,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “We are excited to begin our initial launch of the Lap-Band® 2.0 FLEX that will ultimately demonstrate the real-world benefits of the new FLEX technology, which acts as a relief valve, to alleviate discomfort from swallowing large pieces of food, eliminating the need for in-office band adjustments. We believe, based on current surgeon feedback, that the Lap-Band® 2.0 FLEX will lead to increased demand for Lap-Band® surgery and will become a growth catalyst the Lap-Band® franchise and the company.”
Dr. Smith, a veteran surgeon utilizing the Lap-Band® system and Lap-Band® patient, shared his anticipation and positive outlook on the Lap-Band® 2.0 FLEX, “As a long-time practitioner of the Lap-Band® System, I have anticipated utilizing the Lap-Band® 2.0 FLEX with great interest. I believe it will improve the patient experience by minimizing the need for manual band adjustments, especially when related to the urgent need to relieve food obstructions. Specifically, pieces of food that were once too large to pass through the narrowed passage can now pass through easily because of the new FLEX technology, since it allows the band to relax momentarily and then return to its resting diameter. This ability for self-correction makes the Lap-Band® 2.0 FLEX a better long-term weight loss solution for my patients and I look forward to increasing its usage in my practice, going forward.”
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include the statements that we expect that the Lap-Band® 2.0 FLEX will lead to increased demand for Lap-Band® surgery and will become a growth catalyst for the company. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
FAQ
What is the ticker symbol of ReShape Lifesciences mentioned in the PR?
What is the Lap-Band® 2.0 FLEX designed to do?
Who successfully performed the first surgeries using Lap-Band® 2.0 FLEX?
What benefits does the new FLEX technology offer according to the PR?
How does Dr. Smith perceive the Lap-Band® 2.0 FLEX?
